Creative Planning’s Adamas Pharmaceuticals ADMS Stock Holding History

Creative Planning’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$48K	–	2738
2021 Q1	$48K	Buy	+10,000	New	+$52.2K	﹤0.01%	2359
2020 Q4	–	Sell	-20,000	Closed	-$82K	–	2507
2020 Q3	$82K	Hold	20,000	–	–	﹤0.01%	1855
2020 Q2	$51K	Hold	20,000	–	–	﹤0.01%	1762
2020 Q1	$58K	Hold	20,000	–	–	﹤0.01%	1613
2019 Q4	$76K	Hold	20,000	–	–	﹤0.01%	1783
2019 Q3	$102K	Hold	20,000	–	–	﹤0.01%	1713
2019 Q2	$124K	Sell	20,000 -200	-1%	-$1.15K	﹤0.01%	1721
2019 Q1	$144K	Buy	+20,200	New	+$182K	﹤0.01%	1644
2017 Q3	–	Sell	-258	Closed	-$5K	–	4077
2017 Q2	$5K	Buy	+258	New	+$4.27K	﹤0.01%	4028
2017 Q1	–	Sell	-200	Closed	-$3K	–	5002
2016 Q4	$3K	Buy	+200	New	+$3.09K	﹤0.01%	4196
2016 Q3	–	Sell	-26	Closed	–	–	4795
2016 Q2	$0	Hold	26	–	–	﹤0.01%	4585
2016 Q1	$0	Sell	26 -23	-47%	-$387	﹤0.01%	4618
2015 Q4	$1K	Buy	+49	New	+$825	﹤0.01%	4286

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning's ADMS Position: Q2 2021 in Review

Creative Planning sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 10,000 shares — an estimated $48K sold.

Creative Planning first reported a position in ADMS in Q4 2015 and held it in 13 quarters. The position peaked at $144K in Q1 2019. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

Creative Planning reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Creative Planning sold 10,000 Adamas Pharmaceuticals shares in Q2 2021, an estimated $48K.
Creative Planning first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 13 quarters.
Creative Planning's Adamas Pharmaceuticals position peaked at $144K in Q1 2019.
67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Creative Planning's 13F filing for Q2 2021, filed 4 Aug 2021.